These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16412400)

  • 1. Controversies regarding hormone therapy: Insights from inflammation and hemostasis.
    Koh KK; Yoon BK
    Cardiovasc Res; 2006 Apr; 70(1):22-30. PubMed ID: 16412400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study.
    Koh KK; Han SH; Shin MS; Ahn JY; Lee Y; Shin EK
    Eur Heart J; 2005 Jul; 26(14):1362-8. PubMed ID: 15872028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
    Lakoski SG; Herrington DM
    Climacteric; 2005 Dec; 8(4):317-26. PubMed ID: 16390766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a place for postmenopausal hormone therapy use in women with lupus?
    Gompel A; Piette JC
    Panminerva Med; 2008 Sep; 50(3):247-54. PubMed ID: 18927529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
    Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM
    Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women.
    Koh KK; Horne MK; Cannon RO
    Thromb Haemost; 1999 Aug; 82(2):626-33. PubMed ID: 10605760
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
    Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM
    Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease.
    Rossouw JE
    Ann N Y Acad Sci; 2006 Nov; 1089():444-53. PubMed ID: 17261787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
    Połać I; Borowiecka M; Wilamowska A; Nowak P
    Gynecol Endocrinol; 2013 Feb; 29(2):165-8. PubMed ID: 23116237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHI risks: any relevance to menopause management?
    Burger HG
    Maturitas; 2007 May; 57(1):6-10. PubMed ID: 17368974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women.
    Sezer Ozer K; Erenus M; Yoldemir T
    Climacteric; 2009 Feb; 12(1):66-71. PubMed ID: 19012050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hormone replacement therapy in postmenopausal women: all the treatments are not the same].
    Ribot C; Trémollieres F
    Gynecol Obstet Fertil; 2007 May; 35(5):388-97. PubMed ID: 17392010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Stramba-Badiale M
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hormone treatment on hemostasis variables.
    Kluft C
    Climacteric; 2007 Oct; 10 Suppl 2():32-7. PubMed ID: 17882670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
    Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
    Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
    Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
    Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone replacement therapy and the cardiovascular system: on the role of hemostasis].
    Winkler UH
    Zentralbl Gynakol; 1995; 117(10):510-5. PubMed ID: 7491833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.
    Rosano GM; Maffei S; Andreassi MG; Vitale C; Vassalle C; Gambacciani M; Stramba-Badiale M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone therapy and cardiovascular disease--still much to be learnt.
    Mikkola TS; Ylikorkala O
    Gynecol Endocrinol; 2005 Feb; 20(2):116-20. PubMed ID: 15823832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.